Composite medullary and papillary thyroid carcinoma in a patient with MEN 2B: Case report and review of C-cell lesions of the thyroid

Pathology Case Reviews

Volumn 14, Issue 6, 2009, Pages 208-213

  Mete, Ozgur ^a,b   Asa, Sylvia L ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

C cell hyperplasia; Composite medullary and papillary thyroid carcinoma; Medullary thyroid carcinoma

Indexed keywords

(3 IODOBENZYL)GUANIDINE; ADRENALIN; AMYLOID PROTEIN; CALCITONIN; CALCITONIN GENE RELATED PEPTIDE; CARCINOEMBRYONIC ANTIGEN; CHROMOGRANIN A; METHIONINE; NORADRENALIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN RET; RADIOACTIVE IODINE; THREONINE; THYROGLOBULIN; THYROID TRANSCRIPTION FACTOR 1; THYROTROPIN; THYROXINE;

ADRENAL HYPERPLASIA; ADRENAL SCINTISCANNING; ADRENALECTOMY; AMINO ACID SUBSTITUTION; CALCITONIN BLOOD LEVEL; CANCER PATIENT; CANCER RISK; CARCINOGENESIS; CELL HYPERPLASIA; CODON; COMPUTER ASSISTED TOMOGRAPHY; CONGENITAL TUMOR; DEEP VEIN THROMBOSIS; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG UPTAKE; EMBRYO DEVELOPMENT; ENDOCRINE TUMOR; EPITHELIUM; GENETIC COUNSELING; GENETIC RISK; HISTOPATHOLOGY; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; LAPAROSCOPIC SURGERY; LUNG EMBOLISM; LYMPH NODE METASTASIS; MEDULLARY CARCINOMA; MEGACOLON; MUTATIONAL ANALYSIS; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAGANGLIOMA; PARATHYROID TUMOR; PATIENT REFERRAL; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; REVIEW; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID GLAND; THYROID HYPERPLASIA; THYROID PAPILLARY CARCINOMA; THYROID PARAFOLLICULAR CELL; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; URINALYSIS;

EID: 74249095294     PISSN: 10829784     EISSN: 15334015     Source Type: Journal    
DOI: 10.1097/PCR.0b013e3181c75a44     Document Type: Review

References (40)

1. Oertli D, Udelsman R. Surgery of the Thyroid and Parathyroid Glands. New York, NY: Springer; 2007:13-20.
2. Thyroid: Embryological development. [Wikipedia web site]. January, 2008. Available at: http://en.wikipedia.org/wiki/Thyroid. Accessed May 22, 2009.
3. Adams MS, Bronner-Fraser M. Review: the role of neural crest cells in the endocrine system. Endocr Pathol. 2009;20:92-100.
4. Rosai J, Carcangiu ML, DeLellis R. Tumors of the Thyroid Gland. Atlas of Tumor Pathology. 3rd series (fascicle 5). Washington, DC: Armed Forces Institute of Pathology; 1992.
5. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. Lyon, France: IARC Press; 2004.
6. Alwaheeb S, Ghazarian D, Boerner SL, et al. Cutaneous manifestations of thyroid cancer: a report of four cases and review of the literature. J Clin Pathol. 2004;57:435-438.
7. Schäffer R, Müller HA, Pfeifer U, et al. Cytological findings in medullary carcinoma of the thyroid. Pathol Res Pract. 1984;178:461-466.
8. Uribe M, Fenoglio-Preiser CM, Grimes M, et al. Medullary carcinoma of the thyroid gland. Clinical, pathological, and immunohistochemical features with review of the literature. Am J Surg Pathol. 1985;9:577-594.
9. Sambade C, Baldaque-Faria A, Cardoso-Oliveira M, et al. Follicular and papillary variants of medullary carcinoma of the thyroid. Pathol Res Pract. 1988;184:98-107.
10. Cakir M, Altunbas H, Balci MK, et al. Medullary thyroid carcinoma, follicular variant. Endocr Pathol. 2002;13:75-79.
11. Asa SL. My approach to oncocytic tumours of the thyroid. J Clin Pathol. 2004;57:225-232.
12. Rosai J, Kuhn E, Carcangiu ML. Pitfalls in thyroid tumour pathology. Histopathology. 2006;49:107-120.
13. Valenta LJ, Michel-Bechet M, Matson JC, et al. Microfollicular thyroid carcinoma with amyloid rich stroma, resembling the medullary carcinoma of the thyroid (MCT). Cancer. 1977;39:1573-1586.
14. Nelkin BD, de Bustros AC, Mabry M, et al. The molecular biology of medullary thyroid carcinoma. A model for cancer development and progression. JAMA. 1989;261:3130-3135.
15. Mendelsohn G, Wells SA, Baylin SB. Relationship of tissue carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma. An immunohistochemical study in early, localized and virulent disseminated stages of disease. Cancer. 1984;54:657-662.
16. Casciato DA, Territo MC. Manual of Clinical Oncology. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:344-365.
17. Farid NR. Molecular Basis of Thyroid Cancer. New York, NY: Springer; 2004:23-68.
18. Apel RL, Alpert LC, Rizzo A, et al. A metastasizing composite carcinoma of the thyroid with distinct medullary and papillary components. Arch Pathol Lab Med. 1994;118:1143-1147.
19. Nangue C, Bron L, Portmann L, et al. Mixed medullary-papillary carcinoma of the thyroid: report of a case and review of the literature. Head Neck. 2009;31:968-974.
20. Volante M, Papotti M, Roth J, et al. Mixed medullary-follicular thyroid carcinoma. Molecular evidence for a dual origin of tumor components. Am J Pathol. 1999;155:1499-1509.
21. Fischer S, Asa SL. Application of immunohistochemistry to thyroid neoplasms. Arch Pathol Lab Med. 2008;132:359-372.
22. Pastolero GC, Coire CI, Asa SL. Concurrent medullary and papillary carcinomas of thyroid with lymph node metastases. Am J Surg Pathol 1996;20: 245-250.
23. González-Cámpora R, Lopez-Garrido J, Martin-Lacave I, et al. Concurrence of a symptomatic encapsulated follicular carcinoma, an occult papillary carcinoma and a medullary carcinoma in the same patient. Histopathology. 1992;21:380-382.
24. LiVolsi VA. C cell hyperplasia/neoplasia. J Clin Endocrinol Metab. 1997; 82:39-41.
25. Llyod RV. Endocrine Pathology: Differential Diagnosis and Molecular Advances. New Jersey: Humana Press; 2004:153-190.
26. Dotto J, Nosé V. Familial thyroid carcinoma: a diagnostic algorithm. Adv Anat Pathol. 2008;15:332-349.
27. Zambrano E, Holm I, Glickman J, et al. Abnormal distribution and hyperplasia of thyroid C-cells in PTEN-associated tumor syndromes. Endocr Pathol. 2004;15:55-64.
28. McDermott MB, Swanson PE, Wick MR. Immunostains for collagen type IV discriminate between C-cell hyperplasia and microscopic medullary carcinoma in multiple endocrine neoplasia, type 2a. Hum Pathol. 1995;26:1308-1312.
29. Komminoth P. The RET proto-oncogene in medullary and papillary thyroid carcinoma. Molecular features, pathophysiology and clinical implications. Virchows Arch. 1997;431:1-9.
30. Tubbs RR, Stoler MH. Cell and Tissue Based Molecular Pathology. Philadelphia, PA: Churchill Livingstone Elsevier; 2009:296-304.
31. Jhiang SM. The RET proto-oncogene in human cancers. Oncogene. 2000;19: 5590-5597.
32. de Groot JW, Links TP, Plukker JT, et al. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev. 2006;27: 535-560.
33. Allen SM, Bodenner D, Suen JY, et al. Diagnostic and surgical dilemmas in hereditary medullary thyroid carcinoma. Laryngoscope. 2009;119:1303-1311.
34. Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol. 2008;21(suppl 2):37-43.
35. The Genetics of Thyroid Cancer: Medullary thyroid cancer. [Cancer.Net web site]. October 03, 2008. Available at: http://www.cancer.net/. Accessed May 31, 2009.
36. Eng C, Mulligan LM, Healey CS, et al. Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. Cancer Res. 1996;56:2167-2170.
37. Yang KP, Castillo SG, Nguyen CV. C-myc, N-ras, c-erb B: lack of amplification or rearrangement in human medullary thyroid carcinoma and a derivative cell line. Anticancer Res. 1990;10:189-192.
38. Yana I, Nakamura T, Shin E. Inactivation of the p53 gene is not required for tumorigenesis of medullary thyroid carcinoma or pheochromocytoma. Jpn J Cancer Res. 1992;83:1113-1116.
39. Asa SL. How familial cancer genes and environmentally induced oncogenes have changed the endocrine landscape. Modern Pathol. 2001;14:246-253.
40. Tallini G, Asa SL. RET oncogene activation in papillary thyroid carcinoma. Adv Anat Pathol. 2001;8:345-354.